# Koen Augustyns

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 184 papers | 5,030 citations | 41 h-index | 58 g-index |
| 209 ext. papers | 5,729 ext. citations | 4.9 avg, IF | 5.06 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 184 | Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. *Journal of Biological Chemistry*, **2001**, 276, 29839-45 | 5.4 | 223 |
| 183 | Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. *Journal of Biological Chemistry*, **1999**, 274, 3988-93 | 5.4 | 117 |
| 182 | In vitro antioxidant profile of phenolic acid derivatives. *Free Radical Research*, **2002**, 36, 711-6 | 4 | 116 |
| 181 | Fluoro-olefins as peptidomimetic inhibitors of dipeptidyl peptidases. *Journal of Medicinal Chemistry* , **2005**, 48, 1768-80 | 8.3 | 111 |
| 180 | The Unique Properties of Dipeptidyl-peptidase IV (DPP IV I CD26) and the Therapeutic Potential of DPP IV Inhibitors. *Current Medicinal Chemistry*, **1999**, 6, 311-327 | 4.3 | 104 |
| 179 | Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). *Journal of Medicinal Chemistry*, **2014**, 57, 3053-74 | 8.3 | 103 |
| 178 | When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157. *Cell Death and Differentiation*, **2017**, 24, 1100-1110 | 12.7 | 102 |
| 177 | Synthesis and evaluation of caffeic acid amides as antioxidants. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 215-7 | 2.9 | 102 |
| 176 | Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. *ACS Medicinal Chemistry Letters*, **2013**, 4, 491-6 | 4.3 | 86 |
| 175 | Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors. *Journal of Medicinal Chemistry*, **1999**, 42, 1041-52 | 8.3 | 80 |
| 174 | Inhibitors of the Purine Salvage Pathway: A Valuable Approach for Antiprotozoal Chemotherapy?. *Current Medicinal Chemistry*, **2010**, 17, 2456-81 | 4.3 | 79 |
| 173 | The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. *Current Medicinal Chemistry*, **2005**, 12, 971-98 | 4.3 | 78 |
| 172 | Regulation of intestinal permeability: The role of proteases. *World Journal of Gastroenterology*, **2017**, 23, 2106-2123 | 5.6 | 75 |
| 171 | Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents. *Current Pharmaceutical Design*, **2001**, 7, 1117-41 | 3.3 | 71 |
| 170 | Molecular, functional and structural properties of the prolyl oligopeptidase of Trypanosoma cruzi (POP Tc80), which is required for parasite entry into mammalian cells. *Biochemical Journal*, **2005**, 388, 29-38 | 3.8 | 68 |
| 169 | Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein. *Peptides*, **2008**, 29, 1472-8 | 3.8 | 67 |
| 168 | Natural substrates of dipeptidyl peptidase IV. *Advances in Experimental Medicine and Biology*, **2000**, 477, 67-87 | 3.6 | 63 |

| | | | |
|---|---|---|---|
| 167 | Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). *Biochemical Journal*, **2005**, 386, 315-24 | 3.8 | 62 |
| 166 | Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. *Basic Research in Cardiology*, **2013**, 108, 350 | 11.8 | 61 |
| 165 | Incorporation of hexose nucleoside analogues into oligonucleotides: synthesis, base-pairing properties and enzymatic stability. *Nucleic Acids Research*, **1992**, 20, 4711-6 | 20.1 | 61 |
| 164 | Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. *Biological Chemistry*, **2011**, 392, 189-98 | 4.5 | 59 |
| 163 | Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator. *Journal of Medicinal Chemistry*, **2004**, 47, 2411-3 | 8.3 | 59 |
| 162 | Adhesion of PLGA or Eudragit/PLGA nanoparticles to Staphylococcus and Pseudomonas. *International Journal of Pharmaceutics*, **2008**, 349, 234-40 | 6.5 | 57 |
| 161 | Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes. *Expert Opinion on Therapeutic Patents*, **2003**, 13, 499-510 | 6.8 | 56 |
| 160 | Novel Ferroptosis Inhibitors with Improved Potency and ADME Properties. *Journal of Medicinal Chemistry*, **2016**, 59, 2041-53 | 8.3 | 54 |
| 159 | Synthesis and antiplasmodial activity of aminoalkylamino-substituted neocryptolepine derivatives. *Journal of Medicinal Chemistry*, **2009**, 52, 2979-88 | 8.3 | 54 |
| 158 | Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: isoindoline containing inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 4159-62 | 2.9 | 52 |
| 157 | Dipeptidyl peptidase 8/9-like activity in human leukocytes. *Journal of Leukocyte Biology*, **2007**, 81, 1252-7 | 6.5 | 51 |
| 156 | A New Approach Towards the Synthesis of 3-Amino-6-(hetero)arylpyridazines Based on Palladium Catalyzed Cross-coupling Reactions. *Tetrahedron*, **2000**, 56, 1777-1781 | 2.4 | 48 |
| 155 | Acyclic oligonucleotides: possibilities and limitations. *Tetrahedron*, **1993**, 49, 7223-7238 | 2.4 | 48 |
| 154 | Synthesis and anti-HIV evaluation of 2$3Sdideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2$3Sdideoxynucleosides. *Journal of Medicinal Chemistry*, **1990**, 33, 1833-9 | 8.3 | 48 |
| 153 | Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. *Cell Death and Disease*, **2017**, 8, e2904 | 9.8 | 47 |
| 152 | Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery. *Current Topics in Medicinal Chemistry*, **2007**, 7, 621-35 | 3 | 47 |
| 151 | Influence of the incorporation of (S)-9-(3,4-dihydroxybutyl)adenine on the enzymatic stability and base-pairing properties of oligodeoxynucleotides. *Nucleic Acids Research*, **1991**, 19, 2587-93 | 20.1 | 47 |
| 150 | Irreversible inhibition of dipeptidyl peptidase 8 by dipeptide-derived diaryl phosphonates. *Journal of Medicinal Chemistry*, **2007**, 50, 5568-70 | 8.3 | 44 |

| | | | |
|---|---|---|---|
| 149 | Inhibitors Targeting RIPK1/RIPK3: Old and New Drugs. *Trends in Pharmacological Sciences*, **2020**, 41, 209-224 | 13.4 | 43 |
| 148 | Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?. *Journal of Medicinal Chemistry*, **2011**, 54, 5737-46 | 8.3 | 43 |
| 147 | Prolyl oligopeptidase of Trypanosoma brucei hydrolyzes native collagen, peptide hormones and is active in the plasma of infected mice. *Microbes and Infection*, **2010**, 12, 457-66 | 9.3 | 43 |
| 146 | Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. *Journal of Medicinal Chemistry*, **2007**, 50, 6638-46 | 8.3 | 43 |
| 145 | ATG4B inhibitors with a benzotropolone core structure block autophagy and augment efficiency of chemotherapy in mice. *Biochemical Pharmacology*, **2017**, 138, 150-162 | 6 | 42 |
| 144 | Prolylisoxazoles: potent inhibitors of prolyloligopeptidase with antitrypanosomal activity. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 2875-8 | 2.9 | 41 |
| 143 | Rapid parallel synthesis of dipeptide diphenyl phosphonate esters as inhibitors of dipeptidyl peptidases. *ACS Combinatorial Science*, **2003**, 5, 336-44 | | 41 |
| 142 | Gamma-amino-substituted analogues of 1-[(S)-2,4-diaminobutanoyl]piperidine as highly potent and selective dipeptidyl peptidase II inhibitors. *Journal of Medicinal Chemistry*, **2004**, 47, 2906-16 | 8.3 | 39 |
| 141 | Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes. *Expert Opinion on Therapeutic Patents*, **2005**, 15, 1387-1407 | 6.8 | 39 |
| 140 | ClpP Protease, a Promising Antimicrobial Target. *International Journal of Molecular Sciences*, **2019**, 20, | 6.3 | 37 |
| 139 | Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: the pivotal role of vasoactive intestinal peptide. *Peptides*, **2010**, 31, 585-91 | 3.8 | 37 |
| 138 | Synthesis of 2,4-dideoxy-.beta.-D-erythro-hexopyranosyl nucleosides. *Journal of Organic Chemistry*, **1993**, 58, 2977-2982 | 4.2 | 37 |
| 137 | Design, synthesis, and SAR of potent and selective dipeptide-derived inhibitors for dipeptidyl peptidases. *Journal of Medicinal Chemistry*, **2003**, 46, 5005-14 | 8.3 | 36 |
| 136 | Search for substrates for prolyl oligopeptidase in porcine brain. *Peptides*, **2005**, 26, 2536-46 | 3.8 | 35 |
| 135 | Development of potent and selective dipeptidyl peptidase II inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 2825-8 | 2.9 | 35 |
| 134 | Functional role of the conserved active site proline of triosephosphate isomerase. *Biochemistry*, **2006**, 45, 15483-94 | 3.2 | 34 |
| 133 | Searching for New Leads for Tuberculosis: Design, Synthesis, and Biological Evaluation of Novel 2-Quinolin-4-yloxyacetamides. *Journal of Medicinal Chemistry*, **2016**, 59, 6709-28 | 8.3 | 33 |
| 132 | Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues. *Journal of Histochemistry and Cytochemistry*, **2009**, 57, 531-41 | 3.4 | 33 |

| | | | |
|---|---|---|---|
| 131 | Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV. *European Journal of Medicinal Chemistry*, **1997**, 32, 301-309 | 6.8 | 33 |
| 130 | Structural determinants for ligand binding and catalysis of triosephosphate isomerase. *FEBS Journal*, **2001**, 268, 5189-96 | | 33 |
| 129 | Discovery of Novel, Drug-Like Ferroptosis Inhibitors with in Vivo Efficacy. *Journal of Medicinal Chemistry*, **2018**, 61, 10126-10140 | 8.3 | 33 |
| 128 | Intragraft DPP IV inhibition attenuates post-transplant pulmonary ischemia/reperfusion injury after extended ischemia. *Journal of Heart and Lung Transplantation*, **2007**, 26, 174-80 | 5.8 | 31 |
| 127 | Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 3412-7 | 2.9 | 29 |
| 126 | Dipeptide-derived diphenyl phosphonate esters: mechanism-based inhibitors of dipeptidyl peptidase IV. *Biochimica Et Biophysica Acta - General Subjects*, **1996**, 1290, 76-82 | 4 | 29 |
| 125 | Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position. *Journal of Medicinal Chemistry*, **2006**, 49, 5785-93 | 8.3 | 28 |
| 124 | Synthesis of (E)- and (Z)-fluoro-olefin analogues of potent dipeptidyl peptidase IV inhibitors. *Tetrahedron Letters*, **2003**, 44, 6231-6234 | 2 | 28 |
| 123 | N-Arylmethyl substituted iminoribitol derivatives as inhibitors of a purine specific nucleoside hydrolase. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 6752-63 | 3.4 | 27 |
| 122 | Substrate-assisted leaving group activation in enzyme-catalyzed N-glycosidic bond cleavage. *Journal of Biological Chemistry*, **2005**, 280, 14799-802 | 5.4 | 27 |
| 121 | DPP8/DPP9 inhibition elicits canonical Nlrp1b inflammasome hallmarks in murine macrophages. *Life Science Alliance*, **2019**, 2, | 5.8 | 27 |
| 120 | Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases. *World Journal of Gastroenterology*, **2016**, 22, 10275-10286 | 5.6 | 27 |
| 119 | The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors. *Current Medicinal Chemistry*, **1999**, 6, 311-27 | 4.3 | 27 |
| 118 | In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma. *Biochemical Pharmacology*, **2009**, 77, 228-37 | 6 | 26 |
| 117 | Dipeptidyl alpha-fluorovinyl Michael acceptors: synthesis and activity against cysteine proteases. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 6563-6 | 2.9 | 26 |
| 116 | In vivo evaluation of (18)F-labeled TCO for pre-targeted PET imaging in the brain. *Nuclear Medicine and Biology*, **2014**, 41, 513-23 | 2.1 | 25 |
| 115 | Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 1900-8 | 5.9 | 25 |
| 114 | Influence of the Incorporation of 1-(2,3-Dideoxy-Ð-Erythro-Hexopyranosyl)-Thymine on the Enzymatic Stability and Base-Pairing Properties of Oligodeoxynucleotides. *Bulletin Des Soci*Ès *Chimiques Belges*, **2010**, 101, 119-130 | | 25 |

| | | | |
|---|---|---|---|
| 113 | Synthesis of 6-methyl-6H-indolo[3,2-c]isoquinoline and 6-methyl-6H-indolo[2,3-c]isoquinoline: two new unnatural isoquinoline isomers of the cryptolepine series. *Tetrahedron*, **2008**, 64, 11802-11809 | 2.4 | 25 |
| 112 | Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold. *Journal of Medicinal Chemistry*, **2015**, 58, 9238-57 | 8.3 | 24 |
| 111 | Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 4154-8 | 2.9 | 24 |
| 110 | Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 1: Substitution of the glycine carboxylic acid group. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 2553-6 | 2.9 | 23 |
| 109 | -ketoheterocycles as inhibitors of Leishmania mexicana cysteine protease CPB. *ChemMedChem*, **2010**, 5, 1734-48 | 3.7 | 22 |
| 108 | -Fluorinated proline derivatives: potential transition state inhibitors for proline selective serine dipeptidases. *Tetrahedron Letters*, **2003**, 44, 969-972 | 2 | 22 |
| 107 | Development of a novel antibody-tetrazine conjugate for bioorthogonal pretargeting. *Organic and Biomolecular Chemistry*, **2016**, 14, 7544-51 | 3.9 | 21 |
| 106 | Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398. *International Journal of Pharmaceutics*, **2014**, 475, 238-44 | 6.5 | 21 |
| 105 | P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy. *Journal of Medicinal Chemistry*, **2012**, 55, 9856-67 | 8.3 | 21 |
| 104 | The role of the S1 binding site of carboxypeptidase M in substrate specificity and turn-over. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2007**, 1774, 267-77 | 4 | 21 |
| 103 | CD26/dipeptidylpeptidase IV-targeted therapy of acute lung rejection in rats. *Journal of Heart and Lung Transplantation*, **2006**, 25, 1109-16 | 5.8 | 21 |
| 102 | Investigation on the stability of the Dde protecting group used in peptide synthesis: migration to an unprotected lysine. *Chemical Biology and Drug Design*, **1998**, 51, 127-33 | | 20 |
| 101 | Crystal structures of T. vivax nucleoside hydrolase in complex with new potent and specific inhibitors. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2009**, 1794, 953-60 | 4 | 20 |
| 100 | Purification and characterization of dipeptidyl peptidase IV-like enzymes from bovine testes. *Frontiers in Bioscience - Landmark*, **2008**, 13, 3558-68 | 2.8 | 20 |
| 99 | Tozasertib Analogues as Inhibitors of Necroptotic Cell Death. *Journal of Medicinal Chemistry*, **2018**, 61, 1895-1920 | 8.3 | 19 |
| 98 | Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome. *British Journal of Pharmacology*, **2018**, 175, 3516-3533 | 8.6 | 19 |
| 97 | Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1. *Antiviral Research*, **2014**, 101, 113-21 | 10.8 | 19 |
| 96 | Synthesis and biochemical evaluation of guanidino-alkyl-ribitol derivatives as nucleoside hydrolase inhibitors. *European Journal of Medicinal Chemistry*, **2008**, 43, 315-26 | 6.8 | 19 |

| | | | |
|---|---|---|---|
| 95 | Dipeptidyl peptidase II and leukocyte cell death. *Biochemical Pharmacology*, **2006**, 72, 70-9 | 6 | 19 |
| 94 | Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 2: substitution of the glycine part. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 2703-5 | 2.9 | 19 |
| 93 | Synthesis and Evaluation of a Zr-89-Labeled Monoclonal Antibody for Immuno-PET Imaging of Amyloid-Deposition in the Brain. *Molecular Imaging and Biology*, **2016**, 18, 598-605 | 3.8 | 18 |
| 92 | A Convenient One-Pot Preparation of Disubstituted Phosphinic Acids Derived from Simple Amino Acids and Proline. *Synthesis*, **1995**, 1995, 1074-1076 | 2.9 | 18 |
| 91 | Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma. *Pancreatology*, **2016**, 16, 829-38 | 3.8 | 17 |
| 90 | Schistosomicidal and molluscicidal activities of aminoalkylamino substituted neo- and norneocryptolepine derivatives. *Pharmaceutical Biology*, **2012**, 50, 134-40 | 3.8 | 17 |
| 89 | RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680). *Cell Death and Disease*, **2018**, 9, 211 | 9.8 | 16 |
| 88 | Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA). *Bioorganic and Medicinal Chemistry*, **2012**, 20, 1557-68 | 3.4 | 16 |
| 87 | Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 2038-47 | 5.1 | 16 |
| 86 | Primary graft dysfunction in lung transplantation: the role of CD26/dipeptidylpeptidase IV and vasoactive intestinal peptide. *Transplantation*, **2009**, 87, 1140-6 | 1.8 | 16 |
| 85 | Design and evaluation of Trypanosoma brucei metacaspase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 2001-6 | 2.9 | 16 |
| 84 | 1,2,3-Triazolylalkylribitol derivatives as nucleoside hydrolase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 2523-6 | 2.9 | 16 |
| 83 | Synthesis of 1-(2,4-dideoxy-D-erythro-hexopyranosyl)thymine and its incorporation into oligonucleotides. *Bioorganic and Medicinal Chemistry Letters*, **1992**, 2, 945-948 | 2.9 | 16 |
| 82 | Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 11221-11249 | 8.3 | 16 |
| 81 | The power metric: a new statistically robust enrichment-type metric for virtual screening applications with early recovery capability. *Journal of Cheminformatics*, **2017**, 9, 7 | 8.6 | 15 |
| 80 | Reverse transcriptase inhibitors as microbicides. *Current HIV Research*, **2012**, 10, 27-35 | 1.3 | 15 |
| 79 | Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma. *Analytical Biochemistry*, **2010**, 396, 152-4 | 3.1 | 15 |
| 78 | Ischemia/reperfusion injury: The role of CD26/dipeptidyl-peptidase-IV-inhibition in lung transplantation. *Transplantation Proceedings*, **2006**, 38, 3369-71 | 1.1 | 15 |

| | | | |
|---|---|---|---|
| 77 | A new synthetic method for proline diphenyl phosphonates. *Tetrahedron Letters*, **1995**, 36, 3755-3758 | 2 | 15 |
| 76 | Hybridization specificity, enzymatic activity and biological (Ha-ras) activity of oligonucleotides containing 2,4-dideoxy-beta-D-erythro-hexopyranosyl nucleosides. *Nucleic Acids Research*, **1993**, 21, 4670-6 | 20.1 | 15 |
| 75 | Amino Diphenyl Phosphonates as Novel Inhibitors of Escherichia coli ClpP Protease. *Journal of Medicinal Chemistry*, **2019**, 62, 774-797 | 8.3 | 15 |
| 74 | Synthesis of a new branched chain hexopyranosyl nucleoside: 1-[2?,3?-dideoxy-3?-C-(hydroxymethyl)- D-erythro-pentopyranosyl]-thymine. *Tetrahedron*, **1994**, 50, 1189-1198 | 2.4 | 14 |
| 73 | Hexopyranosyl-Like Oligonucleotides. *ACS Symposium Series*, **1994**, 80-99 | 0.4 | 14 |
| 72 | Caspase-3 probes for PET imaging of apoptotic tumor response to anticancer therapy. *Organic and Biomolecular Chemistry*, **2019**, 17, 4801-4824 | 3.9 | 13 |
| 71 | Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP). *ACS Medicinal Chemistry Letters*, **2019**, 10, 1173-1179 | 4.3 | 13 |
| 70 | Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs). *Bioorganic and Medicinal Chemistry*, **2011**, 19, 5924-34 | 3.4 | 13 |
| 69 | Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assay. *Analytical Biochemistry*, **2010**, 403, 114-6 | 3.1 | 13 |
| 68 | Novel drug discovery strategies for atherosclerosis that target necrosis and necroptosis. *Expert Opinion on Drug Discovery*, **2018**, 13, 477-488 | 6.2 | 12 |
| 67 | Vaginal expression of efflux transporters and the potential impact on the disposition of microbicides in vitro and in rabbits. *Molecular Pharmaceutics*, **2014**, 11, 4405-14 | 5.6 | 12 |
| 66 | Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent. *Nuclear Medicine and Biology*, **2014**, 41, 477-87 | 2.1 | 12 |
| 65 | Synthesis of bicyclic N-arylmethyl-substituted iminoribitol derivatives as selective nucleoside hydrolase inhibitors. *ChemMedChem*, **2009**, 4, 249-60 | 3.7 | 12 |
| 64 | Development and evaluation of peptide-based prolyl oligopeptidase inhibitors--introduction of N-benzyloxycarbonyl-prolyl-3-fluoropyrrolidine as a lead in inhibitor design. *FEBS Journal*, **1997**, 250, 177-83 | | 12 |
| 63 | Novel triazine dimers with potent antitrypanosomal activity. *European Journal of Medicinal Chemistry*, **2018**, 143, 306-319 | 6.8 | 12 |
| 62 | Preclinical evaluation of [ In]MICA-401, an activity-based probe for SPECT imaging of in vivo uPA activity. *Contrast Media and Molecular Imaging*, **2016**, 11, 448-458 | 3.2 | 11 |
| 61 | Structure-based protein engineering efforts with a monomeric TIM variant: the importance of a single point mutation for generating an active site with suitable binding properties. *Protein Engineering, Design and Selection*, **2008**, 21, 257-66 | 1.9 | 11 |
| 60 | Synthesis of peptidyl acetals as inhibitors of prolyl endopeptidase. *Bioorganic and Medicinal Chemistry Letters*, **1995**, 5, 1265-1270 | 2.9 | 11 |

| | | | |
|---|---|---|---|
| 59 | The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma. *Clinica Chimica Acta*, **2019**, 495, 154-160 | 6.2 | 10 |
| 58 | Synthesis and preclinical evaluation of an 18F labeled PDE7 inhibitor for PET neuroimaging. *Nuclear Medicine and Biology*, **2015**, 42, 975-81 | 2.1 | 10 |
| 57 | The use of time-averaged 3JHH restrained molecular dynamics (tar-MD) simulations for the conformational analysis of five-membered ring systems: methodology and applications. *Journal of Computational Chemistry*, **2010**, 31, 561-72 | 3.5 | 10 |
| 56 | Screening of a PDE-focused library identifies imidazoles with in vitro and in vivo antischistosomal activity. *International Journal for Parasitology: Drugs and Drug Resistance*, **2019**, 9, 35-43 | 4 | 9 |
| 55 | Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold. *MedChemComm*, **2014**, 5, 1700-1707 | 5 | 9 |
| 54 | Asymmetric synthesis of □-chloro-□,□-diamino- and □,□-aziridino-□-aminoacylpyrrolidines and -piperidines via stereoselective Mannich-type additions of N-(diphenylmethylene)glycinamides across □-chloro-N-sulfinylimines. *Beilstein Journal of Organic Chemistry*, **2012**, 8, 2124-31 | 2.5 | 9 |
| 53 | Structures of purine nucleosidase from Trypanosoma brucei bound to isozyme-specific trypanocidals and a novel metalorganic inhibitor. *Acta Crystallographica Section D: Biological Crystallography*, **2013**, 69, 1553-66 | | 9 |
| 52 | Polymer-assisted solution-phase parallel synthesis of dipeptide p-nitroanilides and dipeptide diphenyl phosphonates. *Tetrahedron Letters*, **2001**, 42, 9135-9138 | 2 | 9 |
| 51 | Synthesis and evaluation of azaproline peptides as potential inhibitors of dipeptidyl peptidase IV and prolyl oligopeptidase. *International Journal of Peptide Research and Therapeutics*, **1995**, 2, 198-202 | | 9 |
| 50 | Inhibitor screening and enzymatic activity determination for autophagy target Atg4B using a gel electrophoresis-based assay. *European Journal of Medicinal Chemistry*, **2016**, 123, 631-638 | 6.8 | 9 |
| 49 | The first potent diphenyl phosphonate KLK4 inhibitors with unexpected binding kinetics. *MedChemComm*, **2015**, 6, 1954-1958 | 5 | 8 |
| 48 | Spectrophores as one-dimensional descriptors calculated from three-dimensional atomic properties: applications ranging from scaffold hopping to multi-target virtual screening. *Journal of Cheminformatics*, **2018**, 10, 9 | 8.6 | 8 |
| 47 | Efforts towards an On-Target Version of the Groebke-Blackburn-Bienaym□ (GBB) Reaction for Discovery of Druglike Urokinase (uPA) Inhibitors. *Chemistry - A European Journal*, **2019**, 25, 12380-12393 | 4.8 | 8 |
| 46 | An essential signal peptide peptidase identified in an RNAi screen of serine peptidases of Trypanosoma brucei. *PLoS ONE*, **2015**, 10, e0123241 | 3.7 | 8 |
| 45 | Synthesis, evaluation and structure-activity relationships of triazine dimers as novel antiviral agents. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 7174-8 | 2.9 | 8 |
| 44 | Improved stability of a novel fluorine-18 labeled TCO analogue for pretargeted PET imaging. *Nuclear Medicine and Biology*, **2019**, 76-77, 36-42 | 2.1 | 7 |
| 43 | From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 5241-8 | 3.4 | 7 |
| 42 | Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling. *European Journal of Medicinal Chemistry*, **2017**, 139, 482-491 | 6.8 | 7 |

| | | | |
|---|---|---|---|
| 41 | Selective Glucocorticoid Receptor Properties of GSK866 Analogs with Cysteine Reactive Warheads. *Frontiers in Immunology*, **2017**, 8, 1324 | 8.4 | 7 |
| 40 | Repositioning the substrate activity screening (SAS) approach as a fragment-based method for identification of weak binders. *ChemBioChem*, **2014**, 15, 2238-47 | 3.8 | 7 |
| 39 | The effect of organ-specific CD26/DPP IV enzymatic activity inhibitor-preconditioning on acute pulmonary allograft rejection. *Transplantation*, **2009**, 88, 478-85 | 1.8 | 7 |
| 38 | Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2,4-diaminobutanoyl)piperidines. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 4777-9 | 2.9 | 7 |
| 37 | AN EFFICIENT SYNTHESIS OF ORTHOGONALLY PROTECTED SPERMIDINE. *Synthetic Communications*, **2002**, 32, 319-328 | 1.7 | 7 |
| 36 | Sugar Modified Oligonucleotides. *Nucleosides & Nucleotides*, **1991**, 10, 587-588 | | 7 |
| 35 | Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 5032-5038 | 2.9 | 7 |
| 34 | Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives. *European Journal of Medicinal Chemistry*, **2018**, 151, 18-26 | 6.8 | 6 |
| 33 | Probing for improved selectivity with dipeptide-derived inhibitors of dipeptidyl peptidases 8 and 9: the impact of P1-variation. *MedChemComm*, **2016**, 7, 433-438 | 5 | 6 |
| 32 | Virtual screening for inhibitors of the human TSLP:TSLPR interaction. *Scientific Reports*, **2017**, 7, 17211 | 4.9 | 6 |
| 31 | Evaluation of phthalazinone phosphodiesterase inhibitors with improved activity and selectivity against Trypanosoma cruzi. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 958-967 | 5.1 | 6 |
| 30 | A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation. *Scientific Reports*, **2020**, 10, 17268 | 4.9 | 6 |
| 29 | Targeting ferroptosis protects against experimental (multi)organ dysfunction and death.. *Nature Communications*, **2022**, 13, 1046 | 17.4 | 6 |
| 28 | Evaluation of [ F]BR420 and [ F]BR351 as radiotracers for MMP-9 imaging in colorectal cancer. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2017**, 60, 69-79 | 1.9 | 5 |
| 27 | Preclinical Evaluation of a Novel F-Labeled dTCO-Amide Derivative for Bioorthogonal Pretargeted Positron Emission Tomography Imaging. *ACS Omega*, **2020**, 5, 4449-4456 | 3.9 | 5 |
| 26 | Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-□-d-Ribose Oxidase (DprE1) Inhibitors. *Journal of Medicinal Chemistry*, **2020**, 63, 5367-5386 | 8.3 | 5 |
| 25 | Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 1159-68 | 5.1 | 5 |
| 24 | Synthesis of □Aziridino □Amino Acid Derivatives and their Stereoselective Ring Transformation to 2-(Aminomethyl)-1-aminocyclopropanecarboxylic Acid Derivatives. *European Journal of Organic Chemistry*, **2014**, 2014, 1220-1226 | 3.2 | 5 |

| | | | |
|---|---|---|---|
| 23 | Decreased levels of active uPA and KLK8 assessed by [ In]MICA-401 binding correlate with the seizure burden in an animal model of temporal lobe epilepsy. *Epilepsia*, **2017**, 58, 1615-1625 | 6.4 | 5 |
| 22 | Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity. *European Journal of Medicinal Chemistry*, **2017**, 125, 890-901 | 6.8 | 5 |
| 21 | In vivo effects of a potent, selective DPPII inhibitor: UAMC00039 is a possible tool for the elucidation of the physiological function of DPPII. *Advances in Experimental Medicine and Biology*, **2006**, 575, 73-85 | 3.6 | 5 |
| 20 | Identification and Characterization of Approved Drugs and Drug-Like Compounds as Covalent ClpP Inhibitors. *International Journal of Molecular Sciences*, **2019**, 20, | 6.3 | 4 |
| 19 | Synthesis and evaluation of novel benzotropolones as Atg4B inhibiting autophagy blockers. *Bioorganic Chemistry*, **2019**, 87, 163-168 | 5.1 | 4 |
| 18 | The use of supersaturation for the vaginal application of microbicides: a case study with dapivirine. *Journal of Pharmaceutical Sciences*, **2014**, 103, 3696-3703 | 3.9 | 4 |
| 17 | Substrate Activity Screening (SAS) and Related Approaches in Medicinal Chemistry. *ChemMedChem*, **2016**, 11, 467-76 | 3.7 | 3 |
| 16 | Exploration of the active site of dipeptidyl peptidase IV from Porphyromonas gingivalis. Comparison with the human enzyme. *Advances in Experimental Medicine and Biology*, **2003**, 524, 29-35 | 3.6 | 3 |
| 15 | Synthesis and electrophysiological characterization of cyclic morphiceptin analogues. *Biochemical Pharmacology*, **2004**, 67, 1887-95 | 6 | 3 |
| 14 | The effect of pharmacological inhibition of Serine Proteases on neuronal networks. *PeerJ*, **2019**, 7, e6796 | 3.1 | 3 |
| 13 | Strecker-Derived Methodology for Library Synthesis of -Acylated Aminonitriles. *ACS Omega*, **2021**, 6, 1328-1338 | 3.9 | 3 |
| 12 | Lead Optimization of Phthalazinone Phosphodiesterase Inhibitors as Novel Antitrypanosomal Compounds. *Journal of Medicinal Chemistry*, **2020**, 63, 3485-3507 | 8.3 | 2 |
| 11 | Carboxylate isosteres for caspase inhibitors: the acylsulfonamide case revisited. *Organic and Biomolecular Chemistry*, **2017**, 15, 7456-7473 | 3.9 | 2 |
| 10 | Lewis Acid Catalyzed Synthesis of N-Protected Diphenyl 1-Aminoalkylphosphonates. *Synthesis*, **2005**, 2005, 634-638 | 2.9 | 2 |
| 9 | and Activity-Based Labeling of Fibroblast Activation Protein with UAMC1110-Derived Probes. *Frontiers in Chemistry*, **2021**, 9, 640566 | 5 | 2 |
| 8 | Local Colonic Administration of a Serine Protease Inhibitor Improves Post-Inflammatory Visceral Hypersensitivity in Rats. *Pharmaceutics*, **2021**, 13, | 6.4 | 2 |
| 7 | In Vivo Amyloid-Imaging in the APPPS1-21 Transgenic Mouse Model with a (89)Zr-Labeled Monoclonal Antibody. *Frontiers in Aging Neuroscience*, **2016**, 8, 67 | 5.3 | 2 |
| 6 | The use of small volume TOC analysis as complementary, indispensable tool in the evaluation of photocatalysts at lab-scale. *Studies in Surface Science and Catalysis*, **2010**, 175, 321-324 | 1.8 | 1 |

| | | | |
|---|---|---|---|
| 5 | The Effect of a Novel Serine Protease Inhibitor on Inflammation and Intestinal Permeability in a Murine Colitis Transfer Model. *Frontiers in Pharmacology*, **2021**, 12, 682065 | 5.6 | 1 |
| 4 | Selective Activity-Based Probes Targeting Fibroblast Activation Protein (FAP). *Proceedings (mdpi)*, **2019**, 22, 84 | 0.3 | |
| 3 | Resistance Profile of the Diaryltriazine Non-nucleoside Reverse Transcriptase Inhibitor and Candidate Microbicide UAMC01398. *AIDS Research and Human Retroviruses*, **2014**, 30, A212-A212 | 1.6 | |
| 2 | The role of CD26/DPP IV in preservation of early pulmonary graft function. *Advances in Experimental Medicine and Biology*, **2006**, 575, 231-5 | 3.6 | |
| 1 | Molecular biochemical characterization of selective glucocorticoid receptor activities of GSK866 analogues with cysteine reactive warheads. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO2-5-6 | 0 | |